On September 21, Shenzhen Enterprise Federation and Shenzhen Enterprise Directors Association released the list of “2022 Shenzhen Top 500 Enterprises”. With outstanding performance in terms of business scale, employees scale, tax payment, social responsibility, etc., Shenzhen Kangzhe Pharmaceutical Co., Ltd. (“Shenzhen Kangzhe”), a wholly-owned subsidiary of China Medical System Holdings Limited (“CMS” or the “Group”) was once again selected, ranking 130. As a local enterprise born and grown in Shenzhen, Shenzhen Kangzhe capitalizes on the global upstream and downstream resources accumulated by the Group to fulfill the mission of “Providing competitive products and services to meet unmet healthcare and aesthetic needs” and benefit more patients with accessible and affordable quality medicines. Being once again selected for the “Shenzhen Top 500 Enterprises” shows the recognition of Shenzhen Kangzhe’s comprehensive strength and brand value. In the future, CMS will continue to proactively seize the opportunities presented by the construction of the Guangdong-Hong Kong-Macao Greater Bay Area and the Pioneering Demonstration […]
Learn More
Recently, the results of the selection of “Top 20 Competitive Chinese Pharmaceutical Listed Companies in 2022” were announced, China Medical System(“CMS”) stood out from the listed pharmaceutical companies and was once again included in the top 20 list. This activity was guided by China Pharmaceutical Enterprise Management Association and jointly launched by HealthCare Executive and Hejun Consulting. The selection of “Top 20 Competitive Chinese Pharmaceutical Listed Companies” has been organized for the 14th consecutive year. It evaluates Companies with ECIRM model of “Entrepreneur, Capital, Industry, Resources and Management” and identifies the ones with comprehensive competitive strength and being able to flexibly adapt its strategy to the industry trend. CMS takes innovation development to adapt to the complex and rapid changing external environment. With 30 years of accumulated commercialization resources in China, including extensive academic resources and deep market understanding, CMS is able to identify unmet clinical needs with sharp business […]
Learn More
In August 2022, the COVID-19 pandemic struck Tibet Autonomous Region and the pandemic situation was complex. China Medical System Holdings Limited (“CMS”) has paid close attention to the pandemic condition, and in order to support the pandemic prevention and control, its subsidiary Tibet Kangzhe Pharmaceutical Development Co. (“Tibet Kangzhe”) has donated several kinds of epidemic prevention materials to the local government, schools and communities, including medical protective clothing, N95 masks, medical gloves and ethanol disinfectant, etc., while quickly organizing its staff to join the volunteer groups to support the transport of anti-epidemic supplies, nucleic acid testing and pandemic prevention propaganda. The Group will continue to pay close attention to the pandemic condition and actively participate in the pandemic prevention and control works, so as to fulfill our mission and responsibility with concrete actions. Under the effective control of the Tibetan government, we look forward to a victory against the pandemic in Tibet.
Learn More